Breathtec Biomedical

Algernon Pharmaceuticals Receives Green Light from DSMB to Conduct Phase 3 Study of Ifenprodil for COVID-19

UF startup Algernon Pharmaceuticals Inc., formerly known as Breathtec Biomedical, a clinical-stage pharmaceutical development company, announced that the external Data and Safety Monitoring Board (“DSMB”) has completed its latest review of the Phase 2b part of the Company’s Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19, and has provided approval for the company to continue on with the Phase 3 part of the study.